Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s Disease!
Wave and Roche neck and neck! This is very good news for Huntingtonians world-wide! We attended a very exciting webcast yesterday! Wave broke some very interesting news and the first part of their trial with Precision HD2 is very promising, says Svein Olaf Olsen President of the International Huntington Association. While Roche´s trial drug attacks […]Read More